Sanofi (SNY) Acquisitions (2023 - 2026)

Sanofi (SNY) posted Acquisitions of -$2.0 billion for Q1 2026, up 84.41% sequentially from -$12.8 billion in Q4 2025.

Sanofi (SNY) Acquisitions (2023 - 2026) Analysis & Trends

Sanofi has reported Acquisitions for 4 years, with the latest figure at -$2.0 billion in Q1 2026.

Quarterly Acquisitions changed N/A year-over-year to -$2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 billion (changed N/A YoY) and the FY2025 annual result came in at -$12.8 billion, down 377.35% from the prior year.
Acquisitions grew to -$2.0 billion in Q1 2026 per SNY's latest filing, from -$12.8 billion in the prior quarter.
Over five years, Acquisitions peaked at -$90.2 million in Q1 2024 and troughed at -$12.8 billion in Q4 2025.
A 4-year average of -$4.2 billion and a median of -$2.7 billion in 2024 frame the typical range for Acquisitions.
The sharpest annual moves came in 2024 and 2025: Acquisitions climbed 20.87% in 2024, then tumbled 376.97% in 2025.
Over 4 years, Acquisitions stood at -$3.4 billion in 2023, then gained by 20.87% to -$2.7 billion in 2024, then sank by 376.97% to -$12.8 billion in 2025, then jumped by 84.41% to -$2.0 billion in 2026.
According to Business Quant data, Acquisitions over the past three periods registered -$2.0 billion, -$12.8 billion, and -$2.7 billion for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Johnson & Johnson	653.66 Bn	632.90 Bn	17.26 Bn	-17.24 Bn
2	AbbVie	470.02 Bn	463.46 Bn	12.70 Bn	-
3	Merck	379.06 Bn	371.92 Bn	12.21 Bn	-
4	Novartis Ag	302.95 Bn	295.26 Bn	11.24 Bn	-
5	Astrazeneca	257.68 Bn	252.78 Bn	12.86 Bn	-
6	Amgen	236.97 Bn	222.98 Bn	7.24 Bn	-
7	Gilead Sciences	182.78 Bn	179.60 Bn	6.22 Bn	11.21 Bn
8	Pfizer	161.51 Bn	149.81 Bn	10.94 Bn	-
9	Gsk	105.54 Bn	101.37 Bn	8.24 Bn	-
10	Sanofi	55.04 Bn	47.66 Bn	10.79 Bn	-

Download Data